Published in Cancer Weekly, June 17th, 1996
The trial will be looking at post-operative adjuvant (supplementary) treatment of breast cancer. Approximately 800 Canadian women will be recruited to the trial, which has been scheduled to begin in summer 1996.
In a randomized fashion, the women receive either the drug tamoxifen by itself, or a combination of tamoxifen and an agent called octreotide. The women will be followed for seven years to ascertain if there is improved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.